These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 16136374)

  • 1. Weekly paclitaxel in patients with CAP-resistant advanced or recurrent endometrial carcinoma: a series of four patients.
    Akizuki S; Katsumata N; Yamanaka Y; Andoh M; Fujiwara Y; Watanabe T
    Int J Clin Oncol; 2005 Aug; 10(4):272-5. PubMed ID: 16136374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary experience with salvage weekly paclitaxel in women with advanced recurrent ovarian carcinoma.
    Dunder I; Berker B; Atabekoglu C; Bilgin T
    Eur J Gynaecol Oncol; 2005; 26(1):79-82. PubMed ID: 15755007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic administration of single weekly paclitaxel in heavily pretreated ovarian cancer patients.
    Yamamoto K; Oogi S; Inoue H; Kudoh K; Kita T; Kikuchi Y
    Curr Med Chem; 2004 Feb; 11(4):425-8. PubMed ID: 14965223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weekly paclitaxel-carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma.
    Vandenput I; Vergote I; Neven P; Amant F
    Int J Gynecol Cancer; 2012 May; 22(4):617-22. PubMed ID: 22426408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009.
    Makker V; Hensley ML; Zhou Q; Iasonos A; Aghajanian CA
    Int J Gynecol Cancer; 2013 Jun; 23(5):929-34. PubMed ID: 23598889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel as a first-line chemotherapy for Japanese women with advanced or recurrent breast cancer: a multi-institutional practice-based study by the Kyushu Breast Cancer Study Group (KBC-SG).
    Ishikawa M; Takamatsu Y; Mitsuyama S; Iwakuma N; Anan K; Umeda S; Tamura K
    Breast Cancer; 2010 Apr; 17(2):131-5. PubMed ID: 19472037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.
    Fennelly D; Aghajanian C; Shapiro F; O'Flaherty C; McKenzie M; O'Connor C; Tong W; Norton L; Spriggs D
    J Clin Oncol; 1997 Jan; 15(1):187-92. PubMed ID: 8996141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of doxorubicin after progression on carboplatin and paclitaxel in advanced or recurrent endometrial cancer: a retrospective analysis of patients treated at the Brazilian National Cancer Institute (INCA).
    Moreira E; Paulino E; Ingles Garces ÁH; Fontes Dias MS; Saramago M; de Moraes Lino da Silva F; Thuler LCS; de Melo AC
    Med Oncol; 2018 Jan; 35(3):20. PubMed ID: 29387971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly 1-h paclitaxel infusion in patients with recurrent endometrial cancer: a preliminary study.
    Nishio S; Ota S; Sugiyama T; Matsuo G; Kawagoe H; Kumagai S; Ushijima K; Nishida T; Kamura T
    Int J Clin Oncol; 2003 Feb; 8(1):45-8. PubMed ID: 12601542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer.
    Hironaka S; Zenda S; Boku N; Fukutomi A; Yoshino T; Onozawa Y
    Gastric Cancer; 2006; 9(1):14-8. PubMed ID: 16557431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A trial of outpatient paclitaxel and carboplatin for advanced, recurrent, and histologic high-risk endometrial carcinoma: preliminary report.
    Price FV; Edwards RP; Kelley JL; Kunschner AJ; Hart LA
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-78-S15-82. PubMed ID: 9346228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
    Rose PG; Smrekar M; Haba P; Fusco N; Rodriguez M
    Am J Clin Oncol; 2008 Oct; 31(5):476-80. PubMed ID: 18838885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study.
    Katsumata N; Noda K; Nozawa S; Kitagawa R; Nishimura R; Yamaguchi S; Aoki D; Susumu N; Kuramoto H; Jobo T; Ueki K; Ueki M; Kohno I; Fujiwara K; Sohda Y; Eguchi F
    Br J Cancer; 2005 Oct; 93(9):999-1004. PubMed ID: 16234823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line intraperitoneal cisplatin-paclitaxel and intravenous ifosfamide in Stage IIIc ovarian epithelial cancer.
    Zylberberg B; Dormont D; Madelenat P; Daraï E
    Eur J Gynaecol Oncol; 2004; 25(3):327-32. PubMed ID: 15171311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer.
    Karagol H; Saip P; Uygun K; Caloglu M; Eralp Y; Tas F; Aydiner A; Topuz E
    Med Oncol; 2007; 24(1):39-43. PubMed ID: 17673810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens.
    Cantù MG; Buda A; Parma G; Rossi R; Floriani I; Bonazzi C; Dell'Anna T; Torri V; Colombo N
    J Clin Oncol; 2002 Mar; 20(5):1232-7. PubMed ID: 11870165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel efficacy and tolerability in second-line treatment of refractory and relapsed ovarian cancer patients.
    Oliverio G; Canuti D; Tononi A; Scarpellini M; Panzini I; Galli I; Ravaioli A
    J Chemother; 1999 Aug; 11(4):301-5. PubMed ID: 10465133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer.
    Pectasides D; Xiros N; Papaxoinis G; Pectasides E; Sykiotis C; Koumarianou A; Psyrri A; Gaglia A; Kassanos D; Gouveris P; Panayiotidis J; Fountzilas G; Economopoulos T
    Gynecol Oncol; 2008 May; 109(2):250-4. PubMed ID: 18299146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
    Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
    Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.